Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-12EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
EMA authorised Yescarta (axicabtagene ciloleucel) from Kite Pharma EU B.V. for treatment of certain B-cell lymphomas including follicular ly…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial update of BGB-21447, a Bcl-2 inhibitor developed by BeOne Medicines, evaluating safety and preliminary activity in mu…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases [NA]
This entry reports an ongoing clinical trial evaluating myeloablative preparative regimens for umbilical cord blood transplantation across s…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma [Phase 1, Phase 2]
Acalabrutinib is being studied as maintenance therapy in a Phase 1/2 trial for large B-cell lymphomas, including diffuse large B-cell lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma [Phase 2]
This document reports on a Phase II clinical trial evaluating the combination of glofitamab with polatuzumab-R-CHP for high-risk diffuse lar…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells [Phase 2]
Phase 2 study investigating fecal microbiota transplant to remodel gut microbiota in patients with relapsed/refractory diffuse large B-cell …
-
CLINICAL_TRIALS other · 2026-03-05Clinical Trial Update: Pembro Plus CAR T-cell Therapy in R/R in PMBCL [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab in combination with CAR T-cell therapy for relapsed/refractory primary mediastinal large B-c…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy [Phase 3]
A Phase 3 trial compares Ronde-cel CD19 CAR T-cell therapy against investigator's choice CD19 CAR T-cell therapy in adults with large B-cell…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) [Phase 1, Phase 2]
Clinical Trial Update on the ALPHA2 Phase 1/2 study evaluating ALLO-501A anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) [Phase 2]
Phase 2 trial TAi-SHAN9 evaluating DZD8586 in relapsed or refractory diffuse large B-cell lymphoma is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 study evaluating feasibility and safety of collecting autologous hematopoietic stem cells and combining them with CAR T-cell thera…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome [Phase 2]
A Phase 2 clinical trial update evaluating the combination of zanubrutinib and lisocabtagene maraleucel for Richter's syndrome, with patient…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma [Phase 1, Phase 2]
This document outlines an ongoing Phase 1/2 dose-escalation and dose-expansion trial of MDX2003 in multiple lymphoma types, including Walden…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral MRT-2359 in Selected Cancer Patients [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trial evaluating MRT-2359 in multiple cancer indications; trial is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update on WZTL-002 CAR T-cells for adults with relapsed large B-cell lymphoma, including DLBCL and related subtypes, …
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Clinical trial update reporting on neurocognitive effects and patient-reported outcomes for axicabtagene ciloleucel in diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma [Phase 1]
Phase 1 trial results show safety and preliminary efficacy for ALLO-501, an allogeneic anti-CD19 CAR-T therapy, in adults with relapsed/refr…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Karyopharm Expanded Access Program for Selinexor
This update covers Karyopharm's Expanded Access Program for selinexor (Xpovio), including eligibility and current availability for listed ca…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) [Phase 1]
A Phase 1 study from Stanford evaluating a CAR-T cell therapy called ceLL to eradicate active residual disease in diffuse large B-cell lymph…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating epcoritamab in combination with loncastuximab tesirine for relapsed/refractory diffuse large B-cell lymphoma is c…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma [NA]
A clinical trial registry entry indicates a study on cognitive impairment in patients with Diffuse Large B-Cell Lymphoma is currently recrui…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma [Phase 2]
This Phase 2 trial evaluates rituximab and pembrolizumab with or without lenalidomide in relapsed follicular lymphoma and diffuse large B-ce…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]
Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies an…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies [Phase 2]
Phase 2 clinical trial update describing a donor stem cell transplant conditioning regimen with treosulfan, fludarabine, and total-body irra…